LPAA

Launch One Acquisition Corp

• PUBT·05/14 21:16

  Launch One net income falls 25.68% to $1.7 million in Q1 FY26

• TipRanks·03/26 20:46

  Launch One Acquisition Secures New Sponsor Funding Facility

• Reuters·03/26 20:06

  Launch One Acquisition enters working capital note with Launch One Sponsor; loan capacity rises to $1.0 million

• TipRanks·02/04 11:33

  Launch One Acquisition, Minovia deal terminated; new target sought

• Reuters·02/04 11:12

  LAUNCH ONE ACQUISITION CORP: PARTIES MUTUALLY AGREED TO TERMINATE BUSINESS COMBINATION AGREEMENT

• Reuters·02/04 11:12

  LAUNCH ONE ACQUISITION CORP: AS OF JAN 30, CO, SPAC REPRESENTATIVE, MINOVIA, SELLER REPRESENTATIVE ENTERED INTO TERMINATION AND RELEASE AGREEMENT

• Benzinga·01/13 14:57

  Minovia Therapeutics Granted Two New U.S. Patents For Its IP Portfolio

• Reuters·01/13 14:52

  Minovia Therapeutics to Merge with Launch One Acquisition Corp. and List on Nasdaq

• Reuters·01/13 14:51

  MINOVIA THERAPEUTICS ANNOUNCES TWO NEW U.S. PATENTS GRANTED, STRENGTHENING ITS MITOCHONDRIAL AUGMENTATION THERAPY PLATFORM

• TipRanks·11/20/2025 13:50

  Minovia’s mitochondrial augmentation tech to be featured at ASH meeting

• Dow Jones·10/15/2025 11:51

  Minovia to Go Public Through Combination With SPAC

• TipRanks·10/15/2025 11:35

  Minovia receives Orphan Drug Designation for MNV-201 in MDS

• Benzinga·10/15/2025 11:32

  FDA Grants Orphan Drug Designation To Minovia Therapeutic's Lead Investigational Compound, MNV-201 For Myelodysplastic Syndrome

• Reuters·10/15/2025 11:30

  MINOVIA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR MNV-201 IN MYELODYSPLASTIC SYNDROME

• Dow Jones·10/15/2025 11:30

  Press Release: Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome